CT-BEQOM
Only half (51%) of U.S. workers say they have felt comfortable discussing pay with their direct managers during the pandemic, while 41% have not. Far more men (62%) than women (44%) have felt comfortable speaking with their manager about their pay, while Baby Boomers (51%) are almost twice as likely as Generation Z (26%) to be willing to broach the subject. These findings are according to beqom’s 2021 Compensation and Culture Report , which uncovered how employee views of total rewards, diversity and inclusion, work-life balance, transparency, and benefits have changed during the COVID-19 pandemic and what employees expect from their employers in 2021 and beyond.
Of employees who were not comfortable speaking with their manager about their compensation during the pandemic, more than a third (37%) said they’re grateful just to have a job and did not think discussing pay would reflect positively, while a quarter (25%) were nervous it would impact their employment status. While in 2018, 46% of employees said they would share or discuss salary with colleagues , including 56% of Millennials, in 2020, that share dropped to 40% overall, with a significant 13% drop among Millennials (43%).
“In a year like 2020, employees may have in fact been justified feeling uneasy discussing their pay, but the gender and age gaps in these responses should be of concern to employers,” said Tanya Jansen, beqom co-founder and CMO. “This reluctance has the potential to exacerbate gender-related pay gaps and to affect not only the retention of but the lifetime earning potential of Gen Z in particular. Because pay equity perceptions have such a strong influence on retention and employee morale, it’s incumbent upon organizations to be more transparent and communicative with employees around compensation.”
Additional findings from the report show that:
More employees than C-Suite executives took a pay cut during the pandemic.
- More than half (51%) of employees experienced a pay cut during the pandemic, and Gen Z (67%) were the most likely to experience a cut.
- Just 24% of employees say their CEO or executive leadership team took a pay cut during the pandemic.
Less than half of employees would take a pay cut to save colleagues’ jobs.
- A majority (55%) of employees would take a pay cut to avoid being furloughed or let go, with Gen Z (61%) and Millennials (57%) most likely to accept cuts.
- Less than half (44%) would take a pay cut if it meant their colleagues would not be furloughed.
Lack of childcare benefits for working parents led to reduced working hours, less career opportunity.
- Nearly half (47%) of working parents were forced to cut down hours, and thus pay, due to childcare obligations, and nearly two in five (39%) considered leaving the workforce.
- Nearly half (48%) of working parents believe their path to promotion has been negatively affected due to managing childcare during the pandemic.
Employees want to know they’re fairly paid within their specific role above all else.
- When it comes to compensation transparency, employees are most interested in understanding the average compensation for every position at their company (37%), compared to the compensation of every member of their team (21%), the compensation of their CEO and executives (17%), and company compensation by demographic (7%).
- Women (42%) are more likely than men (30%) to want to know the average compensation for every position, while men (22%) are more likely than women (13%) to want to know the compensation of the CEO and executives at their company.
Employers should not underestimate the importance of pay transparency or a DE&I strategy for employee retention.
- More than three-quarters of employees would consider switching jobs if another company offered unlimited paid leave (77%), more flexibility in working hours (76%), or remote work post-COVID (77%).
- Nearly half (48%) of employees would also consider switching jobs if another company had a built out DE&I (diversity, equity and inclusion) strategy, and 58% would consider switching for more pay transparency than their current company provides.
To learn more about beqom’s 2021 Compensation & Culture report and view additional findings, download the full report .
View source version on businesswire.com: https://www.businesswire.com/news/home/20210311005090/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Deciphera Announces Oral Presentation of Positive Topline Results from Phase 2a Study of Sapablursen in Polycythemia Vera at the 67th American Society of Hematology (ASH) Annual Meeting6.12.2025 15:30:00 CET | Press release
Results from Phase 2a IMPRSSION study demonstrate sapablursen significantly reduced phlebotomy rate, controlled hematocrit and increased serum hepcidin Sapablursen was generally safe and well tolerated Results support further development of sapablursen in a Phase 3 study Deciphera Pharmaceuticals, a member of Ono Pharmaceutical Co., Ltd. (Headquarters: Osaka, Japan; President and COO: Toichi Takino; “Ono”), today announced the oral presentation of positive results from the Phase 2a IMPRSSION study of sapablursen in patients with polycythemia vera (PV) at the 67th American Society of Hematology (ASH) Annual Meeting, taking place December 6-9, 2025, in Orlando, FL. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251206361611/en/ The results were presented by Ionis Pharmaceuticals, who discovered and developed sapablursen and conducted the IMPRSSION study. In March 2025, Ionis and Ono entered into a license agreement in which On
Protagonist and Takeda Present Longer-Term Data at ASH 2025 Showing Rusfertide Delivers Durable Response and Hematocrit Control in Polycythemia Vera6.12.2025 15:30:00 CET | Press release
52-Week Results from the Phase 3 VERIFY Study of Rusfertide Demonstrated Sustained Hematocrit Control and Response, Defined by Absence of Phlebotomy Eligibility, with No New Safety SignalsThese Data Build on Positive 32-Week Primary Analysis from VERIFY, Which Met its Primary Efficacy Endpoint and All Four Key Secondary EndpointsPatients Crossing Over from Placebo to Rusfertide at 32 Weeks Achieved a Similar Response Rate to Those Initially Randomized to Rusfertide, with 77.9% Achieving Absence of Phlebotomy Eligibility Between Weeks 40-52Four-Year Results from the Combined REVIVE and Long-Term Extension THRIVE Study Demonstrated a 13-Fold Reduction in Annual Rate of Phlebotomies from Baseline Protagonist Therapeutics, Inc. (“Protagonist”) (NASDAQ:PTGX) and Takeda (TSE:4502/NYSE:TAK) announce that new 52-week results from the pivotal Phase 3 VERIFY study evaluating rusfertide in patients with polycythemia vera (PV) will be presented in an oral presentation at the 67th American Society
Vertex Presents New Data on CASGEVY®, Including First-Ever Data in Children Ages 5-11 Years, at the American Society of Hematology Annual Meeting and Announces Plan for Global Regulatory Submissions6.12.2025 13:01:00 CET | Press release
- Data from pivotal studies of CASGEVY in children ages 5-11 years with severe sickle cell disease or transfusion-dependent beta thalassemia demonstrates the transformative potential of the therapy in younger patients -- Efficacy and safety data in children 5-11 years are consistent with the durable and positive benefit/risk profile established from clinical studies in patients 12 years of age and older -- Vertex expects to initiate global regulatory submissions for CASGEVY in children 5-11 years in 1H 2026 - Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced data from multiple studies demonstrating the clinical benefits of CASGEVY® (exagamglogene autotemcel) in people ages 5 years and older living with severe sickle cell disease (SCD) or transfusion-dependent beta thalassemia (TDT). The results, including the first presentation of clinical data from pivotal studies in children ages 5-11 years, and longer-term data from the pivotal studies of people with severe SCD and
Leading Global Scientists Gather at Tengchong Scientists Forum to Explore Innovative Pathways in Frontier Technologies6.12.2025 12:31:00 CET | Press release
The 2025 Tengchong Scientists Forum opened on Saturday in southwest China’s Yunnan Province, convening leading scientists and academic figures to examine innovation across frontier fields including artificial intelligence, biodiversity and quantum technology. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251205499197/en/ Opening ceremony of Tengchong Scientists Forum on 6th December, 2025 Notable participants include Nobel Physics laureate Konstantin Novoselov, Fields Medalist Efim Zelmanov and Turing Award winner Andrew Chi-Chih Yao, who join 127 academicians, 77 university presidents from China and abroad, over 400 scholars and more than 600 entrepreneurs and financiers. The gathering aims to deepen collaboration between cutting-edge research and industrial development. Under the theme “Science · AI changing the World,” the forum features ten sub-forums, academic sessions and thematic events supporting major cooperation p
Lattice Wins 2025 Global Semiconductor Alliance Award6.12.2025 00:49:00 CET | Press release
‒ Named Most Respected Public Semiconductor Company Achieving $100 Million to $500 Million in Annual Sales ‒ Lattice Semiconductor (NASDAQ: LSCC), the low power programmable leader, today announced that it was selected as ‘Most Respected Public Semiconductor Company’ at the 2025 Global Semiconductor Alliance (GSA) Awards. The GSA awards recognize companies that have demonstrated excellence through their success, vision, strategy, and future opportunities in the industry as determined by votes from GSA members. “We are honored to be recognized by the Global Semiconductor Alliance and our peers as one of 2025’s most respected public semiconductor companies. This recognition reflects the dedication of the Lattice team and the trust of our customers, partners, suppliers, and investors. Looking ahead, we remain laser-focused on driving innovation and strengthening our role as the trusted low power programmable leader for semiconductor and system solutions,” said Ford Tamer, Chief Executive
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
